KLRS · Kalaris Therapeutics, Inc.
$4.10
+0.02 (+0.49%)
At close · Aug 27
Market Cap
$99.98M
Shares
23.80M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.10
Open$4.08
Day$4.00–4.19
52W close$3.08–10.98
Avg vol 30d460K
Short int393K · 1.7% float · 6.2d
Short vol43%
Last earningsFeb 15, 2023
DataJan 2025–Aug 2026
Filing10-Q · Aug 11
Raw chart and full-history price indicators begin at the captured split on Jan 16, 2025; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−37%
below
Price vs 50-day avg
−2%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
13%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+18%
trailing
6-month return
−58%
trailing
YTD return
−51%
this year
Relative strength
−73%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.65% of float · ▼ -4.4% MoM · 6.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
57 holders — near 1-yr high, broad support
Squeeze score
54
elevated · 0–100
Fundamentals
EPS growth
+94%
Y/Y
Free cash flow
$-38.6M
Balance sheet
$98.1M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
7.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−37%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
13%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.65% of float · ▼ -4.4% MoM · 6.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
57 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $4 · 13%
Range high $11
vs 200-day avg -37%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KLRS
this stock
Kalaris Therapeutics, Inc.
|
$99.98M | -51.4% | — | — | 1.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +4.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jan 16, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KLRS | -0.5% | +17.8% | -58.3% | +16.8% | -51.4% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -1.6% | +13.9% | -72.9% | +13.6% | -64.5% |
Key facts
CIK
1754068
CUSIP
482929106
13F (30d)
55 filings
55 filers
Visit website
Investor relations